MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell...
Doctors at Omotesando Helene Clinic Publish New Study on Long-Term Safety Surveillance Following High-Dose Intravenous MSC Administration
Continuing clinical data analysis and academic publication in regenerative medicine and ATMP as the Tokyo clinical hub within Helene Bio Group TOKYO, May 29, 2026 /PRNewswire/ -- Medical Corporation HELENE Omotesando Helene Clinic, located in...